SOURCE: Sunwin International Neutraceuticals, Inc.

December 04, 2006 08:00 ET

Sunwin International Neutraceuticals Contracts Leading Scientist to Advance the Development of Hypericin-Based Products for Use in Combating Avian Flu Virus

FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- December 4, 2006 -- Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world's leading producers of the all natural, zero calorie sweetener Stevia in China, announced today Sunwin has contracted a pioneer in the research of the avian flu virus, Dr. Jianping Liang. Dr. Liang is the Dean of the Research Institute of the Chinese Academy of Agricultural Sciences and a Professor of the South China Agricultural University. Dr. Liang was credited with ground breaking early stage research showing Hypericin was successful in treating the avian flu viruses. Dr. Liang will work closely with Sunwin, Shandong Province, and the Central Government agencies to expedite the approval of the use of Sunwin's Hypericin as class I veterinary medicine to treat poultries infected by avian flu viruses. In addition, Dr. Liang, together with Sunwin's scientists, will continue his leading research work for developing Hypericin related medicines, targeting delivery to poultry through various feeds and drinks to neutralize the viruses and to contain potential outbreaks.

In November 2005, Sunwin's research team created two products employing Hypericin as a main component to deter the spread of the avian flu virus. In the same month, the Department of Livestock Farming of the Shandong Province Government submitted a fast-track application to the Livestock Farming Bureau of China Ministry of Agriculture for approval of Sunwin's Hypericin as a class I veterinary medicine to treat strains of the avian flu virus in poultry. While China Ministry of Agriculture has not provided such clearance of our Hypericin as a class I veterinary medicine, Sunwin can distribute Hypericin as a veterinary feed additive within China.

Laiwang Zhang, President and Chairman of Sunwin International Neutraceuticals, stated, "With the leadership from the top scientist of avian flu virus in China, Sunwin has substantially enhanced its leading position in the Hypericin-based veterinary product sector. We have made the necessary preparations to make our company ready to roll out our Hypericin-based product line as soon as we receive approval from the Central Government for our Hypericin as class I veterinary medicine for treating poultry infected by the avian flu viruses. If the Central Government mandates the use of Hypericin-based products in the poultry industry to prevent potential outbreaks of avian flu, we anticipate that revenues and earnings from our veterinary division will be substantially increased for years to come."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) is engaged in the areas of essential traditional Chinese medicine, low-calorie natural sweetener (Stevia), and veterinary medicines and feeds prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality and a hybrid mix of agricultural products and services that meet growing demand. For more info about Sunwin, please visit

Safe Harbor Statement

Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Reported results should not be considered as an indication of future performance. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact Information

  • Contact:
    Steven Silbert
    Executive Vice President
    Tel: 954.724.2944